The CELLS IN MATRIX project, funded by the European (EU) Horizon2020 program, creates an innovative 3D model consisting of living cells and a matrix for the research and development of diabetes drugs: the engineered micro pancreas (EMP).

European (EU) H2020 funded ORGANTRANS project is set to develop a platform with corresponding technologies for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.

European (EU) H2020 funded VANGUARD project is set to generate a tissue engineered bioartificial pancreas, which, due to its high translation potential, meets all the criteria for the next stage from bench to bedside. The developed beta cell replacement therapy will be available to larger numbers of type 1 diabetic patients.